Genelux price target raised to $20 from $10 at Maxim

Maxim raised the firm’s price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating on the shares. The firm is lowering its risk adjustment for olvimulogene nanivacirepvec after the FDA’s acceptance of the BLA resubmission from Replimune (REPL) for RP1 plus nivolumab for the treatment of advanced melanoma progressing on PD-1 based therapy, the analyst tells investors.